Hochschulschrift
Der NK-Zellrezeptor NKG2D als Zielstruktur für eine Antikörper-basierte therapeutische Immunmodulation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Deutsch
- Notes
-
Erscheinungsjahr an der Haupttitelstelle: 2008
Würzburg, Univ., Diss., 2009
- Keyword
-
Antikörper ; Autoimmunität ; Immunmodulation ; Natürliche Killerzelle
Allergie
Immunkrankheit
Phagozyt
Zelle
Cytologie
Eukaryoten
Protoplasma
Eukaryontische Zelle
- Creator
- URN
-
urn:nbn:de:bvb:20-opus-33446
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
Other Objects (12)
Entwicklung, Produktion und präklinische Charakterisierung bispezifischer NKG2D Fusionsproteine zur Immunmodulation von NK und T Zellen zur Therapie von malignen hämatopoetischen Neoplasien
Chronic NKG2D engagement in vivo differentially impacts NK cell responsiveness by activating NK receptors
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
Circulating CD56+ NKG2D+ NK cells and postoperative fertility in ovarian endometrioma
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Fc-optimierte NKG2D-Fusionsproteine zur Induktion von NK-Zell Reaktivität gegen Leukämien
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Zielstruktur Führungsstab des Heeres
Entwicklung, Produktion und präklinische Charakterisierung bispezifischer NKG2D Fusionsproteine zur Immunmodulation von NK und T Zellen zur Therapie von malignen hämatopoetischen Neoplasien
Chronic NKG2D engagement in vivo differentially impacts NK cell responsiveness by activating NK receptors
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
Circulating CD56+ NKG2D+ NK cells and postoperative fertility in ovarian endometrioma
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Fc-optimierte NKG2D-Fusionsproteine zur Induktion von NK-Zell Reaktivität gegen Leukämien
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Zielstruktur Führungsstab des Heeres
Entwicklung, Produktion und präklinische Charakterisierung bispezifischer NKG2D Fusionsproteine zur Immunmodulation von NK und T Zellen zur Therapie von malignen hämatopoetischen Neoplasien
Chronic NKG2D engagement in vivo differentially impacts NK cell responsiveness by activating NK receptors
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
Circulating CD56+ NKG2D+ NK cells and postoperative fertility in ovarian endometrioma
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Fc-optimierte NKG2D-Fusionsproteine zur Induktion von NK-Zell Reaktivität gegen Leukämien
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation